Glomerulonephritis, Poststreptococcal Medication
- Author: Duvuru Geetha, MD, MRCP; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
Medication Summary
Therapy for patients with APSGN is symptomatic in nature and depends on the clinical severity of the illness. The major aims are to control the edema and blood pressure.
During the acute phase of the disease, salt and water should be restricted. If significant edema or hypertension develops, diuretics should be administered. Loop diuretics increase urinary output and consequently improve cardiovascular congestion and hypertension.
For hypertension not controlled by diuretics, calcium channel blockers or angiotensin-converting enzyme inhibitors are generally useful. For malignant hypertension, intravenous nitroprusside or other parenteral agents are used.
The indications for dialysis include life-threatening hyperkalemia and clinical manifestations of uremia. Steroids, immunosuppressive agents, and plasmapheresis are not generally indicated. In patients with rapidly progressive renal failure, a renal biopsy is indicated. If the biopsy findings show evidence of crescentic glomerulonephritis with more than 30% of the glomeruli involved, a short course of intravenous pulse steroid therapy is recommended (500 mg to 1 g/1.73 m2 of methylprednisone qd for 3-5 d). However, no controlled clinical trials have evaluated such therapy. Long-term treatment with steroids or immunosuppressives is not recommended.
Diuretics
Class Summary
Used to control edema and circulatory congestion.
Furosemide (Lasix)
Increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate with increments of 1 mg/kg/dose until a satisfactory effect is achieved.
Calcium channel blockers
Class Summary
In specialized conducting and automatic cells in the heart, calcium is involved in the generation of the action potential. Calcium channel blockers inhibit movement of calcium ions across the cell membrane, depressing both impulse formation (automaticity) and conduction velocity.
Amlodipine (Norvasc)
Relaxes coronary smooth muscle and produces coronary vasodilation, which, in turn, improves myocardial oxygen delivery. Benefits nonpregnant patients with systolic dysfunction, hypertension, or arrhythmias. Can be used during pregnancy if clinically indicated.
Angiotensin-converting enzyme inhibitors
Class Summary
Decrease aldosterone secretion.
Captopril (Capoten)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.
Enalapril (Vasotec)
Competitive inhibitor of angiotensin-converting enzyme. Reduces angiotensin II levels, decreasing aldosterone secretion. Clinical response usually observed within 15 min of administration.
Vasodilators
Class Summary
Used to treat hypertensive emergencies. Vasodilators reduce SVR, which, in turn, may allow forward flow, improving cardiac output.
Nitroprusside (Nitropress)
Produces vasodilation and increases inotropic activity of heart. At higher dosages, may exacerbate myocardial ischemia by increasing heart rate. Should not be used to treat compensatory hypertension (arteriovenous shunt or coarctation of aorta).
Hydralazine (Apresoline)
Decreases systemic resistance through direct vasodilation of arterioles.
Zegers RH, Weigl A, Steptoe A. The death of Wolfgang Amadeus Mozart: an epidemiologic perspective. Ann Intern Med. Aug 18 2009;151(4):274-8, W96-7. [Medline].
Rodriguez-Iturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol. Oct 2008;19(10):1855-64. [Medline].
Ahn SY, Ingulli E. Acute poststreptococcal glomerulonephritis: an update. Curr Opin Pediatr. Apr 2008;20(2):157-62. [Medline].
Wu SH, Liao PY, Yin PL, Zhang YM, Dong L. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol. Jan 2009;174(1):115-22. [Medline]. [Full Text].
Oda T, Tamura K, Yoshizawa N, et al. Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis. Nephrol Dial Transplant. Jul 2008;23(7):2254-9. [Medline].
Bakr A, Mahmoud LA, Al-Chenawi F, et al. HLA-DRB1* alleles in Egyptian children with post-streptococcal acute glomerulonephritis. Pediatr Nephrol. Mar 2007;22(3):376-9. [Medline].
Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol. Jul 2008;23(7):1101-6. [Medline].
Parra G, Rodriguez-Iturbe B, Batsford S, et al. Antibody to streptococcal zymogen in the serum of patients with acute glomerulonephritis: a multicentric study. Kidney Int. Aug 1998;54(2):509-17. [Medline].
Taskesen M, Taskesen T, Katar S, et al. Elevated plasma levels of N-terminal pro-brain natriuretic peptide in children with acute poststreptococcal glomerulonephritis. Tohoku J Exp Med. Apr 2009;217(4):295-8. [Medline]. [Full Text].
Sorger K, Gessler U, Hubner FK, et al. Subtypes of acute postinfectious glomerulonephritis. Synopsis of clinical and pathological features. Clin Nephrol. Mar 1982;17(3):114-28. [Medline].
Batsford SR, Mezzano S, Mihatsch M, et al. Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH?. Kidney Int. Sep 2005;68(3):1120-9. [Medline].
Dedeoglu IO, Springate JE, Waz WR, et al. Prolonged hypocomplementemia in poststreptococcal acute glomerulonephritis. Clin Nephrol. Nov 1996;46(5):302-5. [Medline].
Deen WM, Bridges CR, Brenner BM. Biophysical basis of glomerular permselectivity. J Membr Biol. 1983;71(1-2):1-10. [Medline].
Dorrington KJ, Tanford C. Molecular size and conformation of immunoglobulins. Adv Immunol. 1970;12:333-81. [Medline].
Massry SG, Glassock RJ. Glomerulonephritis associated with infection. In: Massry SG, Glasscock RJ, eds. Textbook of Nephrology. 3rd ed. Baltimore, Md: Williams & Wilkins; 1995:698-703.
Rodriguez-Iturbe B. Postinfectious glomerulonephritis. Am J Kidney Dis. Jan 2000;35(1):XLVI-XLVIII. [Medline].
Shrier RW, Gottschalk CW, eds. Diseases of the Kidney. Vol 2. 6th ed. Boston, Mass: Little, Brown & Company; 1997:1579- 84.
Silva FG. Acute postinfectious glomerulonephritis and glomerulonephritis complicating persistent bacterial infection. In: Jennette JC, Olson JL, Schwartz MM, eds. Heptinstall's Pathology of the Kidney. Vol 1. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1998:389-455.
Wiwanitkit V. Why is acute post-streptococcal glomerulonephritis more common in the pediatric population?. Clin Exp Nephrol. Jun 2006;10(2):164. [Medline].
Print
